TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing
On May 15, 2024, TAG hosted this webinar on the TB Diagnostics Pipeline: New Tools & Opportunities to Improve Access to Testing.
An Activist’s Guide to Rifapentine – TB Preventive Treatment: 3HP and 1 HP
Rifapentine, an off-patent drug that's been around since the 1960s, is the cornerstone of the two most effective regimens to prevent tuberculosis (TB) in people at risk of the disease.
1/4/6×24 Mid-Campaign Report Launch Webinar
On March 27, 2024, the 1/4/6x24 Campaign and the Stop TB Partnership co-hosted a webinar to launch the Campaign’s new report: Getting Better Faster: Delivering on the Promise of New TB Treatments.
Mid-Campaign Report Highlights What’s Needed to Win Better, Shorter TB Treatments for All by End of 2024
Universal implementation of the best available treatment for drug-susceptible tuberculosis (TB) stands to cut 6.3 million years off total treatment by 2030, a new analysis released today by the 1/4/6x24 Campaign coalition has found.
Getting Better Faster: Delivering on the Promise of New TB Treatments – A Report from the 1/4/6×24 Campaign
This report marks the midway point of the 1/4/6x24 Campaign, which calls for the universal implementation of best available TB regimens — as little as one month or once weekly for TB prevention, four months for drug-susceptible TB, and six months for drug-resistant TB — by the end of 2024.
2024 CROI Tuberculosis Research Round Up
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI). The highlights presented here cover the results of several phase II TB prevention and treatment trials.
Policy Issue Briefs: BARDA and ARPA-H
These two policy briefs explore two as yet untapped sources for drug-resistant tuberculosis (DR-TB) research funding within the U.S. Department of Health and Human Services (HHS).
TPT Community Materials
These free educational materials are designed for community-based and civil society organizations to use to advocate for and teach people about TB preventive treatment (TPT).
Statement from TAG, Global TB CAB on H56:IC31 Phase IIb Trial Results
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.
Report: TB R&D Funding Perilously Off Track of UN Commitments to End Disease by 2030
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.